David Holtzman, MD
Neurology · Saint Louis, MONPI 1972521789
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $120,713 of the $164,847 with a category attached, or 73.2%. 11 manufacturers reported payments, led by Genentech, Inc. at 37.8% of the total. 2025 is the largest year on record at $65,436, more than ten times the $4,832 reported in 2019. Among neurology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 33 payments — averaging $4995.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$62K
- Genentech USA, Inc.$49K
- C2n Diagnostics, LLC$40K
- Pfizer$4K
- Alnylam Pharmaceuticals Inc.$2K
- F. Hoffmann-la Roche AG$2K
- plus $6K from 5 others
Across 1 payment — averaging $25,000,000 each. An ownership or investment interest held by the physician or an immediate family member.
- C2n Diagnostics, LLC$25M
What the payments were for
- Consulting fees$120,71373%
- Speaking & faculty fees$40,90025%
- Travel & lodging$3,1282%
- Food & beverage$1070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 8 | $62,269 |
| Genentech USA, Inc. | 9 | $49,151 |
| C2n Diagnostics, LLC | 4 | $40,000 |
| Pfizer | 2 | $3,900 |
| Alnylam Pharmaceuticals Inc. | 2 | $2,060 |
| F. Hoffmann-la Roche AG | 1 | $1,960 |
| Biogen | 1 | $1,839 |
| AbbVie | 2 | $1,788 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,275 |
| Merck | 1 | $563 |
| Stryker | 2 | $44 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRECIVITYAD2$40,000
- Non-Covered Product$14,832
How this compares
$164,847 in reported general payments places this provider in the 95th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 14 | $307 |
| Donepezil Hcl | 38 | $218 |
| Quetiapine Fumarate | 14 | $106 |
Paid to pharmacies, not to this prescriber.
Other neurology in Saint Louis
- Barry SingerSaint Louis$1.9M
- Mark TullmanSaint Louis$1.5M
- Robert NaismithSaint Louis$677K
- Arun VaradhacharySaint Louis$273K
- Anne CrossSaint Louis$190K
- Ghazala HayatSaint Louis$155K
- Pratap ChandSaint Louis$139K
- Lee TempelSaint Louis$121K
- Salim ChahinSaint Louis$119K
- Jameson HollomanSaint Louis$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.